Page last updated: 2024-09-03

gefitinib and rilpivirine

gefitinib has been researched along with rilpivirine in 1 studies

Compound Research Comparison

Studies
(gefitinib)
Trials
(gefitinib)
Recent Studies (post-2010)
(gefitinib)
Studies
(rilpivirine)
Trials
(rilpivirine)
Recent Studies (post-2010) (rilpivirine)
5,2315662,91958093513

Protein Interaction Comparison

ProteinTaxonomygefitinib (IC50)rilpivirine (IC50)
Gag-Pol polyproteinHIV-1 M:B_HXB2R0.068
Cytochrome P450 1A2Homo sapiens (human)6.1612
Cytochrome P450 3A4Homo sapiens (human)1.7406
Cytochrome P450 2D6Homo sapiens (human)2.3635
Cytochrome P450 2C9 Homo sapiens (human)0.2818
Cytochrome P450 2C19Homo sapiens (human)0.3363
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)0.5
Reverse transcriptase/RNaseH Human immunodeficiency virus 10.0759
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)1.5

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF1

Reviews

1 review(s) available for gefitinib and rilpivirine

ArticleYear
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
    European journal of medicinal chemistry, 2022, Jul-05, Volume: 237

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells

2022